BCAT1 Associates with DNA Repair Proteins KU70 and KU80 and Contributes to Regulate DNA Repair in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Increased expression of branched-chain amino acid (BCAA) transaminase 1 (BCAT1) often correlates with tumor aggressiveness and drug resistance in cancer. We have recently reported that BCAT1 was overexpressed in a subgroup of T-cell acute lymphoblastic (T-ALL) samples, especially those with NOTCH1 activating mutations. Interestingly, BCAT1-depleted cells showed pronounced sensitivity to DNA-damaging agents such as etoposide; however, how BCAT1 regulates this sensitivity remains uncertain. Here, we provide further clues on its chemo-sensitizing effect. Indeed, BCAT1 protein regulates the non-homologous end joining (c-NHEJ) DNA repair pathway by physically associating with the KU70/KU80 heterodimer. BCAT1 inhibition during active repair of DNA double-strand breaks (DSBs) led to increased KU70/KU80 acetylation and impaired c-NHEJ repair, a dramatic increase in DSBs, and ultimately cell death. Our results suggest that, in T-ALL, BCAT1 possesses non-metabolic functions that confer a drug resistance mechanism and that targeting BCAT1 activity presents a novel strategy to improve chemotherapy response in T-ALL patients.
Authors
- Chiara Rompietti (ORCID: https://orcid.org/0000-0003-3907-2186)
- Valeria Tosello (ORCID: https://orcid.org/0000-0001-9560-340X)
- Adonia E. Papathanassiu
- Giorgio Arrigoni (ORCID: https://orcid.org/0000-0002-4103-2733)
- Erich Piovan (ORCID: https://orcid.org/0000-0002-4241-563X)
Institutions
- University of Padua (IT)
- Istituto Oncologico Veneto (IT)
- Aegerion Pharmaceuticals (United States) (US)
- Azienda Ospedale - Università Padova (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2024-12-18
- DOI
- https://doi.org/10.3390/ijms252413571
- Citations
- 1
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Fondazione Italiana per la Ricerca sul Cancro